MNKD — MannKind Corporation

MannKind Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Quarterly Revenues: $90 million, a 15% increase year-over-year.
• FURO6 Net Sales: $15.5 million since its acquisition in October 2025, with strong demand metrics.
• Afrezza Net Sales: $15.3 million, up 3% year-over-year.
• CNS Revenue: $23.5 million, down from $29.4 million year-over-year.
• GAAP Net Loss: $16.6 million ($0.05 per share); Non-GAAP Net Loss: $6.9 million ($0.02 per share), compared to a net income of $13.2 million in Q1 2025.
• Royalty Revenue: Increased by 9% to $32.7 million, supporting capital priorities.
• R&D Expenses: Increased due to ongoing clinical trials, particularly for MNKD-201.

2. Strategic Updates and Business Highlights:

• Partnership with United Therapeutics: Expanded collaboration on ralinepag DPI, with potential development milestones of up to $35 million and a 10% royalty on net sales.
• Afrezza Pediatric Launch: Preparations are underway for a May 29 PDUFA date, with an updated label providing clear dosing guidance.
• FURO6 ReadyFlow Auto-Injector: Anticipated PDUFA date on July 26; expected to significantly enhance patient convenience and adoption.
• Pipeline Development: MNKD-201 (nintedanib DPI) is advancing into Phase 2 trials, with top-line data expected in Q3.

3. Forward Guidance and Outlook:

• FURO6 Revenue Target: Reaffirmed 2026 target of $110 million to $120 million.
• Pediatric Afrezza Launch: Expected to drive significant growth if approved, with a focus on capturing a large share of the pediatric diabetes market.
• Overall Business Transformation: Transitioning from a single-product company to a diversified portfolio with multiple FDA-approved products.

4. Bad News, Challenges, or Points of Concern:

• Q1 Revenue Decline: Seasonal factors led to a typical Q1 decline due to annual deductible resets, impacting prescription fills and doses.
• Disruptions from Reorganization: Transitioning field teams for upcoming launches caused customer disruptions, impacting sales growth.
• Competitive Pressures: New competitors in the market for FURO6, though initial reports suggest limited impact on market share.
• Increased Expenses: Higher SG&A and R&D expenses due to planned commercial investments and integration costs from the SC Pharma acquisition.

5. Notable Q&A Insights:

• Ralinepag DPI Development: The company is confident in progressing with the formulation and has been working on it since August 2025.
• Adoption Curves Post-Approval: Anticipated gradual adoption for both Afrezza pediatrics and FURO6 auto-injector, with significant impacts expected in Q3 and Q4.
• Integration of FURO6 into Discharge Protocols: The process is lengthy, ranging from six to fifteen months, requiring engagement with various stakeholders in healthcare systems.
• Market Dynamics: The potential for combination therapies in IPF was discussed, with confidence in the unique positioning of their inhaled therapies.

Overall, MannKind Corporation is navigating challenges while positioning itself for significant growth through strategic partnerships, product launches, and a diversified pipeline.